The microbiome, encompassing a vast array of microorganisms inhibiting the human body, has garnered significant attention for its role in health and disease. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions. However, while awareness of the microbiome seems to be growing and acceptance of its potential benefits is increasing, adoption remains varied.
In this report, The analyst assesses the current landscape of microbiome-based therapeutics in the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) and examines healthcare professionals’ opinions and utilization of these therapies.
In this report, The analyst assesses the current landscape of microbiome-based therapeutics in the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) and examines healthcare professionals’ opinions and utilization of these therapies.
Scope
Study objectives:
- Examine the current utilization practices of microbiome-based therapies
- Assess the barriers and opportunities associated with the use of microbiome-based therapies
- Measure expected use of microbiome-based therapies in the future
- Identify major players in the microbiome industry
- Analyze market trends and deal-making activities in the microbiome sector
- Overview marketed and pipeline products
Reasons to Buy
- Develop business strategies by understanding the trends shaping and driving the global microbiome-targeting therapy market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global microbiome-targeting therapy market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Understand the challenges and strategies impacting the development of microbiome-targeting therapy agents in preclinical studies and clinical trials.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the classes of microbiome-targeting therapy and indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
- 1.Executive Summary
- 2.Study Design
2.2. Respondent Mix
2.3. Respondent Profiles
- 3.Microbiome Overview
3.2. Microbiome-Targeted Therapies
3.3. Microbiome Value Chain - Microbiome-Targeted Therapies
3.4. Oral LBPs
3.5. LBPs and Postbiotics
3.6. Bacteriophages
3.7. Fecal Microbiota Transplantation
3.8. Trends Impacting Microbiome Research
3.9. Examples of Companies Playing an Active Role in Microbiome Development
3.10. Filings - Microbiome
3.11. Jobs - Microbiome
- 4.Deal-Making Activities in Microbiome
4.2. Deals - M&A Related to Microbiome
4.3. Deals - Strategic Partnerships Related to Microbiome
4.4. Deals - Funding Related to Microbiome
- 5.Current Therapies and Pipeline Products
5.2. Marketed Therapies - US
5.3. Clinical Trials - Top Five Indications for Microbiome
5.4. Late-Stage Microbiome Therapies - 7MM
- 6.Current and Future Use of Microbiome-Based Therapies
6.2. Current and Future Use of Microbiome - France
6.3. Current and Future Use of Microbiome - Germany
6.4. Current and Future Use of Microbiome - Italy
6.5. Current and Future Use of Microbiome - Spain
6.6. Current and Future Use of Microbiome - UK
6.7. Current and Future Use of Microbiome - Japan
- 7.Familiarity and Satisfaction with Microbiome Therapies
7.2. Patient Familiarity with Microbiome-Based Therapies
- 8.Future Considerations
8.2. Evaluating the Microbiome Hype
8.3. Conditions Poised to Benefit the Most from Microbiome-Based Treatments
8.4. Importance of the Microbiome for Human Health
- 9.Summary of Key Findings
9.2. Telemedicine - Other Remarks
- 10.Appendix
10.2. Abbreviations
10.3. Related Reports
- 11.About the Authors
- 12.Contact the Publisher
12.2. About the Analyst
12.3. A Connected Platform for a Dynamic World
